Laekna (HKSE:02105) EBIT per Share : HK$-0.76 (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Laekna EBIT per Share?

Laekna's EBIT per Share for the six months ended in Dec. 2024 was HK$-0.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.76.

During the past 3 years, the average EBIT per Share Growth Rate was -6.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Laekna's EBIT per Share or its related term are showing as below:

HKSE:02105' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -6.9 Med: -6.9 Max: -6.9
Current: -6.9

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Laekna was -6.90% per year. The lowest was -6.90% per year. And the median was -6.90% per year.

HKSE:02105's 3-Year EBIT Growth Rate is ranked worse than
68.07% of 1237 companies
in the Biotechnology industry
Industry Median: 8.1 vs HKSE:02105: -6.90

Laekna's EBIT for the six months ended in Dec. 2024 was HK$-116.26 Mil.

Laekna EBIT per Share Historical Data

The historical data trend for Laekna's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna EBIT per Share Chart

Laekna Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EBIT per Share

-2.35

-2.23

-1.83

-0.75

Laekna Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBIT per Share	Get a 7-Day Free Trial			-1.37	-2.87	-0.42	-0.43	-0.32

Laekna EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Laekna's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-268.276	/	357.626
=	-0.75

Laekna's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-116.258	/	359.271
=	-0.32

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.76

Laekna (HKSE:02105) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Laekna EBIT per Share Related Terms

Thank you for viewing the detailed overview of Laekna's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Laekna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

4U4:Germany

Address

No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203

Website

https://www.laekna.com

Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.

Executives

Orbimed Advisors Iii Limited	2102 Investment manager
Orbimed Asia Gp Iii, L.p.	2102 Investment manager
Orbimed Asia Partners Iii, L.p.	2102 Investment manager
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo	2101 Beneficial owner
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si	2101 Beneficial owner
Laekna Wonderland Limited	2101 Beneficial owner
Lu Chris Xiangyang	2501 Other
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc.	2101 Beneficial owner
Liu Zeng	2201 Interest of corporation controlled by you
Ealex Llc	2101 Beneficial owner
Futu Trustee Limited	2301 Trustee

Laekna Headlines

No Headlines